Melanoma-associated antigen A family peptide-HLA complex (MAGE-A/HLA complex)

The Melanoma-associated antigen A (MAGE-A) family comprises a group of cancer-testis antigens (CTAs) that are typically expressed during embryonic development and in adult germ cells but are aberrantly re-expressed in various cancers (Source: UniProt, P43358). Because germ cells in the testis do not express MHC Class I molecules, MAGE-A proteins are effectively tumor-specific when processed into peptide epitopes and presented by Human Leukocyte Antigen (HLA) molecules on the surface of malignant cells (Source: PubMed, PMID: 31535021). This MAGE-A/HLA complex serves as a critical target for advanced immunotherapies, particularly T-cell receptor (TCR) engineered T-cell therapies like Afamitresgene autoleucel, which targets MAGE-A4 (Source: FDA, 2024). These therapies are designed to recognize the specific peptide-HLA configuration, triggering a potent cytotoxic immune response against tumors such as synovial sarcoma and non-small cell lung cancer (Source: PubMed, PMID: 34343960). Clinical development in this space requires precise patient selection based on both the presence of a compatible HLA allele (e.g., HLA-A*02) and the confirmed expression of the relevant MAGE-A antigen (Source: NIH, NCT04044859). A significant challenge in targeting this family is the potential for off-target toxicity, as high sequence homology among MAGE members or other self-proteins can lead to severe cross-reactivity with vital organs (Source: PubMed, PMID: 23943471).

Other names

MAGE-A family antigensCancer-testis antigen MAGE-AMAGE-A peptide-MHC complexMAGE-A epitopesMelanoma-associated antigen A

T-cell receptor (TCR) engineered T-cell therapy and cancer vaccines targeting specific MAGE-A peptides presented by compatible HLA molecules to induce tumor-specific cytotoxicity.